These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26767751)

  • 1. Comments on 'Use of composite endpoints in clinical trials' by Abdul J. Sankoh, Haihong Li and Ralph B. D'Agostino, Sr.
    Gómez G; Gómez-Mateu M
    Stat Med; 2016 Jan; 35(2):317-8. PubMed ID: 26767751
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of composite endpoints in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2016 Jan; 35(2):319-20. PubMed ID: 26767752
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of composite endpoints in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2014 Nov; 33(27):4709-14. PubMed ID: 24833282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to deal with multiple endpoints in clinical trials.
    Neuhäuser M
    Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALS endpoints. Survival.
    Cedarbaum J
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():79-83. PubMed ID: 15512880
    [No Abstract]   [Full Text] [Related]  

  • 7. Strong control over multiple endpoints: are we adding value to the assessment of medicines?
    Stone A; Chuang-Stein C
    Pharm Stat; 2013; 12(4):189-91. PubMed ID: 23703978
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
    Lonn E
    Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comments on 'Sample size for equivalence trials: a case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona.
    Sun X; Li X; Chen J
    Stat Med; 2012 Jul; 31(15):1652-3; author reply 1654. PubMed ID: 22711252
    [No Abstract]   [Full Text] [Related]  

  • 10. Some remaining challenges regarding multiple endpoints in clinical trials.
    Snapinn S
    Stat Med; 2017 Dec; 36(28):4441-4445. PubMed ID: 28664566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comments on 'Current issues in non-inferiority trials' by Thomas R. Fleming, Statistics in Medicine, DOI: 10.1002/sim.2855.
    Koch GG
    Stat Med; 2008 Feb; 27(3):333-42. PubMed ID: 17530625
    [No Abstract]   [Full Text] [Related]  

  • 12. Dealing with multiple endpoints.
    Dueck A; Novotny PJ
    Curr Probl Cancer; 2006; 30(6):298-306. PubMed ID: 17123881
    [No Abstract]   [Full Text] [Related]  

  • 13. Surrogate and mediating endpoints: current status and future directions.
    Prentice RL
    J Natl Cancer Inst; 2009 Feb; 101(4):216-7. PubMed ID: 19211455
    [No Abstract]   [Full Text] [Related]  

  • 14. Composite and multicomponent end points in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2017 Dec; 36(28):4437-4440. PubMed ID: 28675919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina, R. B. D'Agostino Sr, R. B. D'Agostino Jr, R. S. Vasan, Statistics in Medicine (DOI: 10.1002/sim.2929).
    Greenland P
    Stat Med; 2008 Jan; 27(2):188-90. PubMed ID: 17579927
    [No Abstract]   [Full Text] [Related]  

  • 16. Comments on 'Sample size for equivalence trials: A case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona, Statistics in Medicine 2008; 27:3743-3754.
    Kohberger RC
    Stat Med; 2009 Jan; 28(1):177-8, author reply 178-9. PubMed ID: 18937271
    [No Abstract]   [Full Text] [Related]  

  • 17. Examining the Influence of Component Outcomes on the Composite at the Design Stage.
    Brown PM; Ezekowitz JA
    Circ Cardiovasc Qual Outcomes; 2018 Jun; 11(6):e004419. PubMed ID: 29860234
    [No Abstract]   [Full Text] [Related]  

  • 18. Planning and evaluating clinical trials with composite time-to-first-event endpoints in a competing risk framework.
    Rauch G; Beyersmann J
    Stat Med; 2013 Sep; 32(21):3595-608. PubMed ID: 23553898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninferiority hypotheses and choice of noninferiority margin.
    Ng TH
    Stat Med; 2008 Nov; 27(26):5392-406. PubMed ID: 18680173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter to the editor.
    Wu B; de Leon AR
    Biom J; 2013 Sep; 55(5):807-12. PubMed ID: 23754190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.